ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ONKURE THERAPEUTICS, INC. (OKUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.34% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-12
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.30%, a 38.71% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 3.80%, a 26.67% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.90%, a 116.67% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 3.10%, a 210.00% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.34%, a 14.21% increase from fiscal 2024.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.80%, a 11.83% decline from fiscal 2023.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.31%, a 26.76% increase from fiscal 2022.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.40%, a 277.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 4.34% 10-K · filed 2026-03-12 | |||||||
| 2024-12-31 | 3.80% 10-K · filed 2026-03-12 | |||||||
| 2023-12-31 | 4.31% 10-K · filed 2025-03-10 | 4.00% 10-K · filed 2024-03-28 | ||||||
| 2023-09-30 | 4.30% 10-Q · filed 2023-11-13 | 4.00% 10-Q · filed 2023-11-13 | ||||||
| 2023-06-30 | 3.80% 10-Q · filed 2023-08-10 | 3.80% 10-Q · filed 2023-08-10 | ||||||
| 2023-03-31 | 3.90% 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | 3.40% 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | 3.10% 10-Q · filed 2023-11-13 | 2.50% 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-10 | 2.30% 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 1.80% 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 0.90% 10-K · filed 2023-03-27 | 0.88% 10-K · filed 2022-03-23 | ||||||
| 2021-09-30 | 1.00% 10-Q · filed 2022-11-08 | 0.70% 10-Q · filed 2022-11-08 | 0.69% 10-Q · filed 2021-11-12 | |||||
| 2021-06-30 | 0.70% 10-Q · filed 2022-08-09 | 0.70% 10-Q · filed 2022-08-09 | 0.67% 10-Q · filed 2021-08-11 | |||||
| 2021-03-31 | 0.70% 10-Q · filed 2022-05-10 | 0.66% 10-Q · filed 2021-05-20 | ||||||
| 2020-12-31 | 1.00% 10-K · filed 2022-03-23 | |||||||
| 2020-09-30 | 1.07% 10-Q · filed 2021-11-12 | |||||||
| 2020-06-30 | 1.00% 10-Q · filed 2021-08-11 | |||||||
| 2020-03-31 | 1.44% 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |